1. Avoiding Double-Counting in Pharmacoeconomic Studies

   • Magnus Johannesson

   Leading Article 25 November 2012 Pages: 385 - 388

2. The Effect of Pharmacoeconomics on Company Research and Development Decisions

   • Henry Grabowski

   Leading Article 25 November 2012 Pages: 389 - 397

3. The Economic Aspects of Drug Delivery in Asthma

   • R. John Massie
   • Craig M. Mellis

   Review Article 25 November 2012 Pages: 398 - 407

4. Cost Considerations in the Pharmacological Prevention and Treatment of Stroke

   • Andrei V. Alexandrov
   • Liliana T. Smurawska
   • Paul Oh

   Review Article 25 November 2012 Pages: 408 - 418

5. Constraints on Antidepressant Prescribing and Principles of Cost-Effective Antidepressant Use

   • John A. Henry
   • Carol A. Rivas

   Review Article 25 November 2012 Pages: 419 - 443

6. Drug Treatments for Maintaining Remission in Crohn’s Disease

   • Giacomo Trallori
   • Andrea Messori

   Original Research Article 25 November 2012 Pages: 444 - 453

7. Autologous Peripheral Blood Progenitor-Cell Transplantation versus Autologous Bone Marrow Transplantation for Adults and Children with Non-Leukaemic Malignant Disease

   • Anne-Gaëlle Le Corroller
   • Catherine Faucher
   • Jean-Paul Moatti

   Original Research Article 25 November 2012 Pages: 454 - 463

8. Bootstrap Analyses of Cost Effectiveness in Antidepressant Pharmacotherapy

   • Robert L. Obenchain
   • Catherine A. Melfi
   • Don P. Buesching

   Original Research Article 25 November 2012 Pages: 464 - 472

9. Sumatriptan

   • Allan J. Coukell
   • Harriet M. Lamb

   Adis Pharmacoeconomic Drug Evaluation 25 November 2012 Pages: 473 - 490

10. Interferon-α in Hepatitis C

    • Raymond S. Koff

    Correspondence 25 November 2012 Pages: 491 - 491

11. Interferon-α in Hepatitis C: The Authors’ Reply

    • Andrew Briggs
    • Alan Shiell

    Correspondence 25 November 2012 Pages: 491 - 492

12. Cost Utility in Second-Line Metastatic Breast Cancer

    • Gilles Berdeaux
    • Patrick Hurteloup

    Correspondence 25 November 2012 Pages: 492 - 495

13. Cost Utility in Second-Line Metastatic Breast Cancer: The Authors’ Reply

    • Robert Launois
    • Jeanne Reboul-Marty
    • Jacques Bonneterre

    Correspondence 25 November 2012 Pages: 495 - 497